The investigation, announced September 2, 2026, invites long-term shareholders of the NASDAQ-listed biotech firm to evaluate their standing. Legal representatives Daniel Sadeh and Zachary Halper are spearheading the review, exploring potential avenues for corporate reform, the recovery of company funds, and other financial relief for those impacted by alleged misconduct. The firm operates on a contingent fee basis, meaning investors do not incur out-of-pocket expenses for the initial assessment of their claims.

Halper Sadeh LLC maintains that active shareholder participation remains critical to enforcing transparency and improving oversight mechanisms within publicly traded entities. While prior legal outcomes do not guarantee future success, the firm has a history of litigating securities fraud and corporate malfeasance. Interested parties are encouraged to contact the New York office at One World Trade Center to discuss their rights before potential filing deadlines expire.